Goldenwell Biotech Inc
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.
Goldenwell Biotech Inc (GWLL) - Net Assets
Latest net assets as of June 2025: $-86.84K USD
Based on the latest financial reports, Goldenwell Biotech Inc (GWLL) has net assets worth $-86.84K USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($251.29K) and total liabilities ($338.13K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-86.84K |
| % of Total Assets | -34.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 64.16 |
Goldenwell Biotech Inc - Net Assets Trend (2020–2024)
This chart illustrates how Goldenwell Biotech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Goldenwell Biotech Inc (2020–2024)
The table below shows the annual net assets of Goldenwell Biotech Inc from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-47.24K | -155.76% |
| 2023-12-31 | $84.72K | -57.98% |
| 2022-12-31 | $201.62K | -33.18% |
| 2021-12-31 | $301.71K | +21.38% |
| 2020-12-31 | $248.57K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Goldenwell Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 135733400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.90K | % |
| Other Components | $1.30 Million | % |
| Total Equity | $-47.24K | 100.00% |
Goldenwell Biotech Inc Competitors by Market Cap
The table below lists competitors of Goldenwell Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Crest Builder Holdings Bhd
KLSE:8591
|
$7.20 Million |
|
Mobio Technologies Inc
V:MBO
|
$7.20 Million |
|
Netlinkz Ltd
AU:NET
|
$7.20 Million |
|
Step One Clothing Limited
F:J6H
|
$7.21 Million |
|
Electroprecizia SA
RO:ELZY
|
$7.20 Million |
|
QNB Finans Finansal Kiralama AS
IS:QNBFL
|
$7.20 Million |
|
Itera ASA
OL:ITERA
|
$7.20 Million |
|
SCIUKER FRAMES SPA
F:3K4
|
$7.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Goldenwell Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 84,723 to -47,241, a change of -131,964 (-155.8%).
- Net loss of 131,498 reduced equity.
- Other factors decreased equity by 466.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-131.50K | -278.36% |
| Other Changes | $-466.00 | -0.99% |
| Total Change | $- | -155.76% |
Book Value vs Market Value Analysis
This analysis compares Goldenwell Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.00 | $0.20 | x |
| 2020-12-31 | $0.00 | $0.20 | x |
| 2021-12-31 | $0.00 | $0.20 | x |
| 2022-12-31 | $0.00 | $0.20 | x |
| 2023-12-31 | $0.00 | $0.20 | x |
| 2024-12-31 | $0.00 | $0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Goldenwell Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -94602.88%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-111.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -2.81% | 0.00% | 0.00x | 1.00x | $-31.59K |
| 2020 | -2.54% | 0.00% | 0.00x | 1.00x | $-31.18K |
| 2021 | -38.77% | -732.64% | 0.03x | 1.53x | $-147.15K |
| 2022 | -488.60% | -2060.87% | 0.19x | 1.23x | $-1.01 Million |
| 2023 | -137.97% | -4995.51% | 0.01x | 2.69x | $-125.37K |
| 2024 | 0.00% | -94602.88% | 0.00x | 0.00x | $-126.77K |
Industry Comparison
This section compares Goldenwell Biotech Inc's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $4,768,351,202
- Average return on equity (ROE) among peers: -224.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Goldenwell Biotech Inc (GWLL) | $-86.84K | -2.81% | N/A | $7.20 Million |
| Above Food Ingredients Inc. Common Stock (ABVE) | $-46.26 Million | 0.00% | 0.00x | $18.58 Million |
| The a2 Milk Company Limited (ACOPF) | $58.64 Million | 0.02% | 0.31x | $3.91 Billion |
| Ayujoy Herbals Ltd (AJOY) | $668.89K | -63.57% | 1.39x | $90.84 |
| Alfa S.A.B. de C.V (ALFFF) | $43.29 Billion | 8.20% | 1.29x | $2.16 Billion |
| Amincor Inc (AMNCB) | $1.83 Million | -1769.92% | 18.32x | $2.21K |
| Armanino Foods New (AMNF) | $5.68 Million | 50.87% | 0.65x | $71.04K |
| Amira Nature Foods Ltd (ANFIF) | $171.84 Million | 17.43% | 1.45x | $128.79 |
| AAK AB (publ.) (ARHUF) | $3.56 Billion | 16.89% | 1.80x | $5.07 Billion |
| Artisan Consumer Goods Inc (ARRT) | $9.48K | -513.58% | 0.36x | $279.39K |
| ARYZTA AG (ARZTF) | $632.10 Million | 9.58% | 2.04x | $53.13 Million |